Skip to main content

Firebrick Pharma Health Care

$0.155 0.005 (3.33%)

High

$0.16

Low

$0.15

Trades

7

Turnover

$4,468

Volume

29,243
30 June 2023 at 3:01pm
Register to track FRE and receive email alerts.
FRE Announcements on Price Chart

Latest Announcements

Headline Date
Firebrick Update on AAT Schedule 29 June 2023 at 4:45pm
Cleansing Notice 21 June 2023 at 3:05pm
Change of Director's Interest Notice - Stephen Goodall 21 June 2023 at 3:05pm
Change of Director's Interest Notice - Peter Molloy 21 June 2023 at 3:05pm
Application for quotation of securities - FRE 21 June 2023 at 2:55pm
Results of General Meeting 20 June 2023 at 11:55am
Firebrick Pharma Investor Update on Key Projects 20 June 2023 at 8:45am
Notification of cessation of securities - FRE 16 June 2023 at 8:45am
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment 31 May 2023 at 9:25am
Update on Nasodine AAT Appeal Timetable 29 May 2023 at 6:35pm
Letter to Shareholders & Notice of GM & Proxy Form 15 May 2023 at 12:59pm
Cleansing Notice 9 May 2023 at 11:40am
Application for quotation of securities - FRE 9 May 2023 at 11:35am
Nasodine Patent Allowed in Canada 9 May 2023 at 8:50am
Proposed issue of securities - FRE 1 May 2023 at 8:55am
Proposed issue of securities - FRE 1 May 2023 at 8:45am
Firebrick Raises $1 million via Placement 1 May 2023 at 8:40am
March 2023 Quarterly Activity Report & Appendix 4C 20 April 2023 at 8:45am
Nasodine COVID-19 Trial Concludes Recruitment 3 April 2023 at 10:10am
Cleansing Notice 28 March 2023 at 2:40pm
Application for quotation of securities - FRE 28 March 2023 at 2:40pm
Firebrick Pharma's Phase 3 Trial of Nasodine Resumes 21 March 2023 at 9:10am
FRE files EU Paediatric Investigation Plan for Nasodine 21 February 2023 at 9:45am
Appendix 4D & Half Yearly Report and Accounts 17 February 2023 at 5:15pm
Investor Presentation - Euroz Hartleys Healthcare Forum 1 February 2023 at 7:55pm
December 2022 Quarterly Activity Report & Appendix 4C 19 January 2023 at 9:45am
Nasodine Research Points to Potential Role in CRS 18 January 2023 at 9:30am
Nasodine Appeal Timetable Agreed at AAT Conference 1 December 2022 at 5:30pm
Change of Director's Interest Notice - Phyllis Gardner 24 November 2022 at 4:55pm
Change of Director's Interest Notice - Richard Treagus 24 November 2022 at 4:45pm
Notification regarding unquoted securities - FRE 24 November 2022 at 4:40pm
Notification regarding unquoted securities - FRE 24 November 2022 at 4:35pm
Constitution 24 November 2022 at 12:20pm
Results of Annual General Meeting 23 November 2022 at 4:10pm
Annual General Meeting Presentation 23 November 2022 at 12:55pm
Firebrick CFO and Accounting Change 14 November 2022 at 4:45pm
Nasodine Composition Patent Accepted in Australia 14 November 2022 at 9:15am
Firebrick Receives $1.08m R&D Tax Incentive 9 November 2022 at 8:40am
Proposed issue of securities - FRE 1 November 2022 at 11:25am
Firebrick Update on Nasodine Phase 3 Trial 31 October 2022 at 5:05pm
September 2022 Quarterly Activity Report & Appendix 4C 31 October 2022 at 4:59pm
Nasodine Patent Granted in Singapore 25 October 2022 at 9:05am
Annual Report to Shareholders 21 October 2022 at 5:10pm
Letter to Shareholders & Notice of AGM & Proxy Form 21 October 2022 at 2:10pm
Notification of cessation of securities - FRE 10 October 2022 at 11:10am
Notice of AGM and Closing Date for Director Nominations 28 September 2022 at 2:05pm
Firebrick announces formation of Scientific Advisory Board 14 September 2022 at 8:30am
Corporate Governance Statement 23 August 2022 at 5:35pm
Appendix 4G 23 August 2022 at 5:35pm
Appendix 4E & Annual Report 23 August 2022 at 5:35pm
Register to track FRE and receive email alerts.